1SXP Stock Overview
Develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharmaceutical, biotechnology, and life science industries worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
SCHOTT Pharma AG & Co. KGaA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €31.50 |
| 52 Week High | €43.40 |
| 52 Week Low | €25.64 |
| Beta | 0 |
| 11 Month Change | 13.15% |
| 3 Month Change | -21.84% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0.64% |
Recent News & Updates
Earnings Miss: SCHOTT Pharma AG & Co. KGaA Missed EPS By 18% And Analysts Are Revising Their Forecasts
Jul 01
We Think SCHOTT Pharma KGaA (ETR:1SXP) Can Stay On Top Of Its Debt
Jun 07Calculating The Intrinsic Value Of SCHOTT Pharma AG & Co. KGaA (ETR:1SXP)
Mar 28Shareholder Returns
| 1SXP | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 1.0% | 5.0% | 0.8% |
| 1Y | n/a | -11.5% | 5.5% |
Return vs Industry: Insufficient data to determine how 1SXP performed against the German Life Sciences industry.
Return vs Market: Insufficient data to determine how 1SXP performed against the German Market.
Price Volatility
| 1SXP volatility | |
|---|---|
| 1SXP Average Weekly Movement | 6.9% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 1SXP's share price has been volatile over the past 3 months.
Volatility Over Time: 1SXP's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1884 | 4,672 | n/a | www.schott-pharma.com |
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharmaceutical, biotechnology, and life science industries worldwide. The company offers prefillable glass or polymer syringes, glass vials, cartridges, and ampoules. Its syringe products include syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; and SCHOTT TOPPAC unique, a polymer container.
SCHOTT Pharma AG & Co. KGaA Fundamentals Summary
| 1SXP fundamental statistics | |
|---|---|
| Market cap | €4.74b |
| Earnings (TTM) | €134.63m |
| Revenue (TTM) | €916.32m |
35.2x
P/E Ratio5.2x
P/S RatioIs 1SXP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1SXP income statement (TTM) | |
|---|---|
| Revenue | €916.32m |
| Cost of Revenue | €605.12m |
| Gross Profit | €311.20m |
| Other Expenses | €176.57m |
| Earnings | €134.63m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 29, 2024
| Earnings per share (EPS) | 0.89 |
| Gross Margin | 33.96% |
| Net Profit Margin | 14.69% |
| Debt/Equity Ratio | 31.0% |
How did 1SXP perform over the long term?
See historical performance and comparison